SequelSEC

INTENSITY THERAPEUTICS, INC. INTS

Biological Products, (No Diagnostic Substances) · CIK 0001567264 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$11.97M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

INTENSITY THERAPEUTICS, INC. (INTS) reported net income of -$11.61M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from INTENSITY THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

INTENSITY THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$11.97M-$16.58M-$8.32M-$7.55M
Net income-$11.61M-$16.27M-$10.54M-$7.58M
Research & development$6.78M$10.50M$4.79M$5.13M
Weighted-average diluted sharesshares 1.36MUnavailableshares 8.62Mshares 3.41M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0
Diluted EPS$-8.56$-29.24$-1.38$-2.22
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$5.19M$6.09M$3.53M$2.42M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

INTENSITY THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$11.92M$2.59M$8.56M$1.31M
Total assets$14.10M$4.78M$17.30M$1.76M
Current assets$12.71M$3.36M$15.46M$1.45M
Total liabilities$2.22M$1.86M$4.13M$6.86M
Current liabilities$2.15M$1.76M$3.96M$6.82M
Total equity incl. NCI$11.88M$2.92M$13.16M-$15.10M
Temporary (mezzanine) equityUnavailable$0$0$10.00M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$583.00K$1.22M$3.05M$603.00K

Cash flow

INTENSITY THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$9.23M-$15.22M-$7.20M-$5.48M
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$6.35M-$6.02M$0
Financing cash flow$18.56M$2.90M$20.47M$2.25M
Net change in cash$9.33M-$5.97M$7.24M-$3.23M
Stock-based compensation$2.00M$3.07M$1.40M$1.17M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

INTENSITY THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio5.92x1.92x3.91x0.21x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INTS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.